DocTIS’ study to be presented at the EULAR 2025 Congress in Barcelona
The DocTIS project is proud to announce that a study from its research initiative has been selected for presentation at the EULAR 2025 Congress, taking place from June 11–14, 2025, in Barcelona, Spain. This prestigious annual event, organized by the European Alliance of Associations for Rheumatology (EULAR), is one of the most important gatherings in the field of rheumatology worldwide.
On Friday, June 13, Dr. Antonio Julià, head of the Rheumatology Research Group at the Vall d’Hebron Institute of Research (VHIR), will deliver an oral presentation of the study titled: “DocTIS: A Single-Cell RNA-Seq Atlas of Drug Response to Targeted Therapies”. The presentation will take place in Room B1 of the FIRA Barcelona venue, as part of the session “New Ways of Patient Stratification with Systemic Diseases.”
This study represents a major milestone in the DocTIS initiative. It provides a comprehensive single-cell RNA sequencing (scRNA-Seq) analysis of drug response in immune-mediated inflammatory diseases (IMIDs). For this objective, longitudinal blood samples from 184 patients and 8 healthy controls have been analysed, generating more than 2 million high quality single cell transcriptomes. By examining the responses to six types of targeted therapies, the study revealed distinct immune patterns for each disease and identified key differences between patients who responded well to treatment and those who did not. Overall, the study delivers a detailed map of immune mechanisms associated to drug efficacy in these diseases, paving the way for novel and more precise treatment approaches.
Since its inception in 1947, the EULAR Congress has served as a global stage for presenting cutting-edge science and clinical advancements in rheumatic and musculoskeletal diseases (RMDs). With over 12,000 attendees and hundreds of sessions, posters, and abstract presentations, EULAR brings together an international community of researchers, clinicians, health professionals, industry partners, and patients to exchange knowledge and shape the future of rheumatology care.
The DocTIS project, which aims to improve treatment efficacy in six immune-mediated inflammatory diseases (IMIDs), is pleased to contribute to EULAR 2025 and support the advancement of rheumatology through innovation and collaboration.
